Central Pharma’s acquisition and rebrand

Central Pharma announces the acquisition of Biotechnica

The leading pharmaceutical contract service provider Central Pharma has acquired Biotechnica, the UK’s largest manufacturer of seaweed extract.

The official acquisition was confirmed on Friday 5th February 2021. Established in 1993, Biotechnica offers one of the most comprehensive ranges of agricultural biostimulants and biofertilisers and manufacture bespoke formulations. Central Pharma specialises in the final stages of manufacturing and packaging for the pharmaceutical and nutraceutical industries.

Following the acquisition, Biotechnica is being rebranded to sit under the Central Pharma family and has been renamed, “Central Pharma Biotechnica Limited” furthering the commitment to investing in Biotechnica’s future.

Our old Biotechnica logo


Our new logo


“Our immediate focus is investment, to support growing demand from the existing Biotechnica customers. We are very excited to welcome [Biotechnica’s] experienced team to the Central Pharma family.”

– Alwyn Smit, CEO, Central Pharma